1. Home
  2. AKBA vs FRBA Comparison

AKBA vs FRBA Comparison

Compare AKBA & FRBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • FRBA
  • Stock Information
  • Founded
  • AKBA 2007
  • FRBA 2007
  • Country
  • AKBA United States
  • FRBA United States
  • Employees
  • AKBA N/A
  • FRBA N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • FRBA Major Banks
  • Sector
  • AKBA Health Care
  • FRBA Finance
  • Exchange
  • AKBA Nasdaq
  • FRBA Nasdaq
  • Market Cap
  • AKBA 336.2M
  • FRBA 369.7M
  • IPO Year
  • AKBA 2014
  • FRBA N/A
  • Fundamental
  • Price
  • AKBA $1.82
  • FRBA $14.49
  • Analyst Decision
  • AKBA Strong Buy
  • FRBA Buy
  • Analyst Count
  • AKBA 2
  • FRBA 1
  • Target Price
  • AKBA $5.75
  • FRBA $17.00
  • AVG Volume (30 Days)
  • AKBA 2.4M
  • FRBA 46.8K
  • Earning Date
  • AKBA 11-07-2024
  • FRBA 10-23-2024
  • Dividend Yield
  • AKBA N/A
  • FRBA 1.63%
  • EPS Growth
  • AKBA N/A
  • FRBA 54.36
  • EPS
  • AKBA N/A
  • FRBA 1.60
  • Revenue
  • AKBA $169,879,000.00
  • FRBA $123,433,000.00
  • Revenue This Year
  • AKBA N/A
  • FRBA N/A
  • Revenue Next Year
  • AKBA $6.13
  • FRBA $5.07
  • P/E Ratio
  • AKBA N/A
  • FRBA $9.03
  • Revenue Growth
  • AKBA N/A
  • FRBA 34.10
  • 52 Week Low
  • AKBA $0.80
  • FRBA $11.20
  • 52 Week High
  • AKBA $2.48
  • FRBA $15.87
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 56.59
  • FRBA 46.36
  • Support Level
  • AKBA $1.76
  • FRBA $14.47
  • Resistance Level
  • AKBA $2.02
  • FRBA $15.58
  • Average True Range (ATR)
  • AKBA 0.11
  • FRBA 0.43
  • MACD
  • AKBA -0.02
  • FRBA -0.02
  • Stochastic Oscillator
  • AKBA 40.00
  • FRBA 44.49

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About FRBA First Bank

First Bank is a full-service commercial bank, with an emphasis on providing personal and business financial services to individuals and small to mid-sized businesses. The Bank provides its customers with a variety of financial services targeting all segments of the retail and corporate market. Its Business Banking offers commercial deposit accounts, business loans, online banking, and cash management.

Share on Social Networks: